Renaissance Capital logo

Aerie Pharmaceuticals Priced, Nasdaq: AERI

Clinical-stage biotech developing treatments for glaucoma.

Industry: Health Care

First Day Return: +6.1%

Clinical-stage biotech developing treatments for glaucoma.

Aerie Pharmaceuticals (AERI) Performance

Created with Highcharts 10.3.2Chart context menuAERI vs. IPO Index (IPOUSA)2014201520162017201820192020202120222023202420250%+ 200%-200%+ 400%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index